NEULAND LABORATORIES
|
NEULAND LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| CEPS(Rs) | 253.82 | 280.42 | 168.59 | 87.97 | 93.78 |
| DPS(Rs) | 12.00 | 14.00 | 10.00 | 5.00 | 5.00 |
| Book NAV/Share(Rs) | 1,187.77 | 999.07 | 774.12 | 654.40 | 612.28 |
| Tax Rate(%) | 24.90 | 25.25 | 24.21 | 22.32 | 23.45 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 21.89 | 29.68 | 22.82 | 15.00 | 15.67 |
| EBIT Margin(%) | 24.01 | 26.65 | 19.21 | 10.06 | 13.15 |
| Pre Tax Margin(%) | 23.45 | 25.76 | 18.11 | 8.64 | 11.24 |
| PAT Margin (%) | 17.61 | 19.25 | 13.73 | 6.71 | 8.61 |
| Cash Profit Margin (%) | 22.05 | 23.08 | 18.16 | 11.87 | 12.84 |
| Performance Ratios | |||||
| ROA(%) | 12.97 | 17.59 | 11.04 | 4.71 | 6.31 |
| ROE(%) | 18.54 | 26.38 | 17.84 | 7.85 | 10.79 |
| ROCE(%) | 23.45 | 33.51 | 20.94 | 9.44 | 12.81 |
| Asset Turnover(x) | 0.74 | 0.91 | 0.80 | 0.70 | 0.73 |
| Sales/Fixed Asset(x) | 1.28 | 1.54 | 1.28 | 1.09 | 1.22 |
| Working Capital/Sales(x) | 2.19 | 3.16 | 3.70 | 4.37 | 5.17 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.78 | 0.65 | 0.78 | 0.91 | 0.82 |
| Receivable days | 85.17 | 86.10 | 91.33 | 86.74 | 79.40 |
| Inventory Days | 90.97 | 73.73 | 83.41 | 98.40 | 91.00 |
| Payable days | 137.94 | 114.75 | 110.05 | 116.52 | 111.44 |
| Valuation Parameters | |||||
| PER(x) | 59.57 | 26.86 | 14.12 | 20.64 | 33.22 |
| PCE(x) | 47.58 | 22.40 | 10.67 | 11.67 | 22.27 |
| Price/Book(x) | 10.17 | 6.29 | 2.32 | 1.57 | 3.41 |
| Yield(%) | 0.10 | 0.22 | 0.56 | 0.49 | 0.24 |
| EV/Net Sales(x) | 10.41 | 5.15 | 1.99 | 1.61 | 3.02 |
| EV/Core EBITDA(x) | 44.72 | 16.89 | 8.42 | 10.56 | 17.37 |
| EV/EBIT(x) | 43.35 | 19.32 | 10.36 | 15.97 | 22.96 |
| EV/CE(x) | 9.26 | 5.88 | 2.13 | 1.43 | 2.14 |
| M Cap / Sales | 10.49 | 5.17 | 1.94 | 1.38 | 2.86 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -5.24 | 30.84 | 25.25 | 1.51 | 22.84 |
| Core EBITDA Growth(%) | -27.65 | 68.73 | 94.61 | -11.18 | 54.02 |
| EBIT Growth(%) | -14.64 | 81.56 | 139.20 | -22.38 | 65.42 |
| PAT Growth(%) | -13.32 | 83.51 | 156.21 | -20.85 | 397.40 |
| EPS Growth(%) | -13.32 | 83.51 | 156.21 | -20.85 | 397.40 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.09 | 0.06 | 0.12 | 0.28 | 0.22 |
| Current Ratio(x) | 2.45 | 2.15 | 1.73 | 1.60 | 1.49 |
| Quick Ratio(x) | 1.62 | 1.33 | 1.10 | 0.87 | 0.82 |
| Interest Cover(x) | 42.74 | 29.68 | 17.51 | 7.09 | 6.89 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.05 | 0.18 | 0.06 |
Compare Financial Ratios of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹22,960.1 Cr | 3.4% | 5.2% | 47.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹446,792.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,152.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,915.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹116,354.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,681.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 3.4% |
5.2% |
47.6% |
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses
